The stock of Trillium Therapeutics Inc (TSE:TR) is a huge mover today! About 13,071 shares traded hands. Trillium Therapeutics Inc (TSE:TR) has declined 16.39% since April 11, 2016 and is downtrending. It has underperformed by 20.32% the S&P500.
The move comes after 9 months positive chart setup for the $78.64 million company. It was reported on Nov, 15 by Barchart.com. We have $19.19 PT which if reached, will make TSE:TR worth $62.91M more.
More news for Trillium Therapeutics Inc (TSE:TR) were recently published by: Marketwatch.com, which released: “Trillium Therapeutics Inc.” on August 24, 2009. Etfdailynews.com‘s article titled: “Trillium Therapeutics Inc. (TRIL): Finding The Next Blockbuster Biotech Stock” and published on June 23, 2015 is yet another important article.
Trillium Therapeutics Inc is a Canada clinical stage immuno-oncology firm developing therapies for the treatment of cancer. The company has a market cap of $78.64 million. The Company’s SIRPaFc program, which is under Phase I clinical trial, is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the fragment crystallizable (Fc) region of a human immunoglobulin (IgG1). It currently has negative earnings. It acts as a soluble decoy receptor, preventing CD47 from delivering its inhibitory signal.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.